ADX 10059 hydrochloride

Pricing Availability   Qty
Description: Negative allosteric modulator of mGlu5 receptors
Alternative Names: Raseglurant
Chemical Name: 2-[(3-Fluorophenyl)ethynyl]-4,6-dimethyl-3-pyridinamine hydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for ADX 10059 hydrochloride

ADX 10059 hydrochloride is reported to be a negative allosteric modulator at the mGlu5 receptor. Analog of MPEP (Cat. No. 1212).

Compound Libraries for ADX 10059 hydrochloride

ADX 10059 hydrochloride is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for ADX 10059 hydrochloride

M. Wt 276.74
Formula C15H13FN2.HCl
Storage Desiccate at RT
Purity ≥99% (HPLC)
CAS Number 757949-98-7
PubChem ID 18454771
InChI Key BDXXMGYKLQZXOU-UHFFFAOYSA-N
Smiles CC1=CC(C)=NC(C#CC2=CC=CC(F)=C2)=C1N.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for ADX 10059 hydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 6.92 25
DMSO 27.67 100

Preparing Stock Solutions for ADX 10059 hydrochloride

The following data is based on the product molecular weight 276.74. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.61 mL 18.07 mL 36.14 mL
5 mM 0.72 mL 3.61 mL 7.23 mL
10 mM 0.36 mL 1.81 mL 3.61 mL
50 mM 0.07 mL 0.36 mL 0.72 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for ADX 10059 hydrochloride

References for ADX 10059 hydrochloride

References are publications that support the biological activity of the product.

Weiss et al (2011) 6-Aryl-3-pyrrolidinylpyridines as mGlu5 receptor negative allosteric modulators. Bioorg.Med.Chem.Lett. 21 4891 PMID: 21757343

Keywood et al (2009) A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut. 58 1192 PMID: 19460767

Marin and Goadsby (2010) Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? Expert Opin.Invest.Drugs 19 555 PMID: 20218930


If you know of a relevant reference for ADX 10059 hydrochloride, please let us know.

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Modulators

Keywords: ADX 10059 hydrochloride, ADX 10059 hydrochloride supplier, metabotropics, glutamate, receptor, 5, mglur5, mglu5, NAMs, negative, allosteric, modulators, ADX10059, Raseglurant, Glutamate, (Metabotropic), Group, I, Receptors, 4416, Tocris Bioscience

Citations for ADX 10059 hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for ADX 10059 hydrochloride. Do you know of a great paper that uses ADX 10059 hydrochloride from Tocris? Please let us know.

Reviews for ADX 10059 hydrochloride

There are currently no reviews for this product. Be the first to review ADX 10059 hydrochloride and earn rewards!

Have you used ADX 10059 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.